MX2009006410A - Conjugados de polimero-oligonucleotido, proteina y/o peptido. - Google Patents

Conjugados de polimero-oligonucleotido, proteina y/o peptido.

Info

Publication number
MX2009006410A
MX2009006410A MX2009006410A MX2009006410A MX2009006410A MX 2009006410 A MX2009006410 A MX 2009006410A MX 2009006410 A MX2009006410 A MX 2009006410A MX 2009006410 A MX2009006410 A MX 2009006410A MX 2009006410 A MX2009006410 A MX 2009006410A
Authority
MX
Mexico
Prior art keywords
oligonucleotide
peptide
protein
polymer conjugates
polyethyleneglycol
Prior art date
Application number
MX2009006410A
Other languages
English (en)
Inventor
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Andreas Mitsch
Dargmar Fischer
Original Assignee
Antisense Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisense Pharma Gmbh filed Critical Antisense Pharma Gmbh
Publication of MX2009006410A publication Critical patent/MX2009006410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Se describe un conjugado o compuesto que comprende polietilenglicol y un oligonucleátido, en donde al menos un polietilenglicol se liga al extremo 5´ del oligonucleátido y al menos un polietilenglicol se liga al extremo 3´ del oligonucleátido, en donde el peso molecular del polietilenglico ligado al extremo 5´ y 3´ del oligonucleátido es idéntico y es <5000 Da, o en donde el peso molecular del polietilenglicol ligado al extremo 5´ y 3´ del oligonucleátio es diferente.
MX2009006410A 2006-12-22 2007-12-21 Conjugados de polimero-oligonucleotido, proteina y/o peptido. MX2009006410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127100A EP1935428A1 (en) 2006-12-22 2006-12-22 Oligonucleotide-polymer conjugates
PCT/EP2007/064494 WO2008077956A2 (en) 2006-12-22 2007-12-21 Oligonucleotide-, protein and/or peptide-polymer conjugates

Publications (1)

Publication Number Publication Date
MX2009006410A true MX2009006410A (es) 2009-06-23

Family

ID=37969567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006410A MX2009006410A (es) 2006-12-22 2007-12-21 Conjugados de polimero-oligonucleotido, proteina y/o peptido.

Country Status (7)

Country Link
US (1) US20110136893A1 (es)
EP (2) EP1935428A1 (es)
JP (1) JP5401323B2 (es)
AU (1) AU2007337994B2 (es)
CA (1) CA2684165C (es)
MX (1) MX2009006410A (es)
WO (1) WO2008077956A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011117353A1 (en) 2010-03-24 2011-09-29 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
JP2013531981A (ja) * 2010-06-11 2013-08-15 アンチセンス・ファーマ・ゲーエムベーハー 選択的オリゴヌクレオチド修飾の方法
EP2453017A1 (en) 2010-11-12 2012-05-16 Antisense Pharma GmbH Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
RU2564855C2 (ru) * 2011-04-26 2015-10-10 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Способ получения пэгилированных олигонуклеотидов
CA2908096C (en) 2013-03-27 2022-05-03 Isarna Therapeutics Gmbh Modified tgf-beta oligonucleotides
PT2978846T (pt) 2013-03-27 2020-04-21 Isarna Therapeutics Gmbh Oligonucleótido de tgf-beta modificado para utilização num método de prevenção e/ou tratamento de uma doença oftálmica
PL2978844T3 (pl) * 2013-03-27 2021-01-25 Isarna Therapeutics Gmbh Modyfikowane oligonukleotydy tgf-beta2
JP6584868B2 (ja) * 2015-02-25 2019-10-02 学校法人 関西大学 ゲル素材及びその製造方法
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer
KR20220039639A (ko) * 2020-09-21 2022-03-29 오토텔릭바이오 주식회사 안티센스 올리고뉴클레오타이드

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
DE3788914T2 (de) * 1986-09-08 1994-08-25 Ajinomoto Kk Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
WO1989005358A1 (en) * 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
US5403711A (en) * 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5623065A (en) * 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5220007A (en) * 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5714331A (en) * 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
CN1048254C (zh) * 1993-12-09 2000-01-12 托马斯杰弗逊大学 用于将预定的改变引入靶基因中的化合物
US5652356A (en) * 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US20030175238A1 (en) * 2000-06-30 2003-09-18 Narendra Bam Chemokine conjugates
EP1581548A4 (en) * 2002-11-21 2008-04-23 Archemix Corp MULTIVALENT APTAMER THERAPEUTIC WITH IMPROVED PHARMACODYNAMIC PROPERTIES AND METHOD FOR THE PRODUCTION AND USE THEREOF
RS20050501A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
ZA200709237B (en) * 2005-05-05 2009-04-29 Antisense Pharma Gmbh Dosage of oligonucleotides

Also Published As

Publication number Publication date
AU2007337994B2 (en) 2011-08-25
US20110136893A1 (en) 2011-06-09
JP5401323B2 (ja) 2014-01-29
EP2121028A2 (en) 2009-11-25
WO2008077956A2 (en) 2008-07-03
AU2007337994A1 (en) 2008-07-03
EP1935428A1 (en) 2008-06-25
CA2684165C (en) 2013-12-03
CA2684165A1 (en) 2008-07-03
WO2008077956A3 (en) 2008-11-20
JP2010512773A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
MX2009006410A (es) Conjugados de polimero-oligonucleotido, proteina y/o peptido.
WO2006124737A3 (en) Molecular constructs suitable for targeted conjugates
MY154909A (en) Novel thiophene derivatives
IL179633A0 (en) Drug compositions, fusions and conjugates
NZ588884A (en) Cross-linkers and their uses
IL229304A (en) Compounds 1 &#39;, 3&#39; - Imaging Converts - 4 - Phenyl - 3, 4, 5, 6 - Tetrahydro - 2h, 1&#39;h, [1, 4 &#39;] Bipyridinyl - 2&#39; - lozenges, pharmaceutical preparations containing them and their use
MY148231A (en) Leptomycin derivatives
TW200700406A (en) Novel thiophene derivatives
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
EA200800657A1 (ru) Способ приготовления очищенных конъюгатов лекарственных средств
TW200716552A (en) Novel thiophene derivatives
TW200738670A (en) Novel thiophene derivatives
IL192948A0 (en) Novel pyridine derivatives
TW200635576A (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2009099670A3 (en) Oligomer-cannabinoid conjugates
EP3381445A3 (en) Aqueous formulation of antibody stablised by antioxidants for parenteral administration
FR2891314B1 (fr) Bras d&#39;injecteur anti-cokefaction.
DE602005026182D1 (de) Herstellung von insulinkonjugaten
MX2010004899A (es) Conjugados de neurturina novedosos para uso farmaceutico.
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
GB2453402A (en) Bis-pyyrolo[2.1.-c] benzodiazepine-anthraquinone conjugates as antitumour agents and a process for the preparation thereof
ATE506571T1 (de) Hydrolyseresistente polyamidzusammensetzungen und daraus geformte artikel
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates
BRPI0313645A2 (pt) composições de inalação com relações de droga elevadas.

Legal Events

Date Code Title Description
FG Grant or registration